Portfolio

PORTFOLIO COMPANIES

DigitalDx Ventures invests in companies focused on impacting health with diagnostics for conditions that include breast cancer, mental health, kidney health, maternal health, infectious disease, cardiac health, multi-cancer screening, and brain health (with the first indication in Alzheimer's).

PORTFOLIO COMPANY NEWS

(Click on title to see full article)

March 22, 2022 — NephroSant Launches Two-Year Study of 2,000 Kidney Transplant Recipients
March 4, 2022 — NephroSant promotes QSant kidney study
March 3, 2022 — NephroSant Publishes Real-World Evidence Showing Potential to Improve the Detection of Early Kidney-Transplant Rejection Events
September 22, 2021 — NephroSant Secures Medicare Coverage for QSant, the First Urine-based Kidney Transplant Rejection Test, and Plans 2022 Launch
March 19, 2021 — NephroSant Readies Launch of Kidney Transplant Rejection Assay
March 16, 2021 — NephroSant Announces $16 Million Series A, Led by DaVita Venture Group

March 31, 2021 — Women's Health Tech Wednesdays | Digital DX Ventures and Trayt
January 19, 2020 — Founder Series with Malekeh Amini, CEO of Trayt: Challenges of running a mental health startup
March 28, 2019 — InnovatorMD
April 20, 2018 — Trayt debuts mobile app to track and help treat autism, ADHD
August 23, 2018 — Tech exec works to help treat kids' brain disorders

February 6, 2023 — U.N. Hosts Climate and Health Scientists at Plenary on Vision of Future Pandemic Preparedness
August 23, 2022 — Biotia has raised an oversubscribed $8 million Series A round led by OCA Ventures.
August 15, 2022 — Biotia Selected By Mayo Clinic Platform To Accelerate The Success of Its AI Diagnostic Software
August 2, 2022 — Twist Bioscience and Biotia Receive Expanded Emergency Use Authorization to Report Genetic Variants of SARS-CoV-2
April 9, 2021 — A National Open Genomics Consortium for the COVID-19 Response
November 19, 2020 — Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus
June 15, 2020 — Utilizing Augmented Intelligence to Drive Optimal Decisions Throughout the Specialty and Rare Disease Product Lifecycle
September 22, 2017 — Metagenomic characterization of ambulances across the USA

July 1, 2022 — Danish Startup GLX Analytix Prepares for Commercialization With Seed Investment
June 14, 2022 — GLX Analytix Receives Funds from DigitalDx Ventures, Vaekstfonden & CBC Investment Group to Accelerate Growth
2019 — GLX Analytix has been voted Roche Startup of the Year 2019

May 24, 2022 — Silicon Valley based Diagnostics Company AEENA Dx Welcomes new Board Member
October 29, 2020 — Aeena Dx Welcomes Robert Weigle as CEO

October 6, 2022 -- BIOINFRA and 20/20 GeneSystems Announce U.S. Technology License for Enhanced Multi-Cancer Early Detection Blood Test
September 30,2022 — Now You Can Screen for Cancer Sooner Rather Than Later
August 16, 2022 — Inc. -- Inc. 5,000 Names Maryland's Fastest Growing Companies in 2022
July 30, 2022 — BioBuzz Show -- Gaithersburg’s 20/20 GeneSystems Honored As It Opens ‘First-of-its-Kind’ Diagnostics Incubator in Montgomery County
September 29, 2021 — LabPulse.com -- 20/20 GeneSystems Launches Clinical Lab Innovation Facility
September 29, 2021 — CLP magazine -- 20/20 GeneSystems Launches Clinical Lab Innovation Facility
August 17, 2021 — Inc. -- 20/20 GeneSystems, Inc. Ranks No. 770 on the 2021 Inc. 5000, With Three-Year Revenue Growth of 640 Percent
August 13, 2020 — NBC4 -- Maryland Legislators Urge More Aggressive Use of Antibody Tests as Local Company Aims to Advance Research
April 10, 2020 — ABC7 -- Can antibody blood tests confirm you're immune, get you out of quarantine?
October 15, 2020 — 20/20 GeneSystems Launching First COVID-19 Rapid Antibody Test Authorized by FDA for Point-of-Care Use
March 27, 2020 — Baltimore Business Journal -- These Md. companies are racing to create coronavirus testing supplies

March 9, 2023 — Delphi DiagnosticsTM Inc Announces a Publication Showing that the Sensitivity-to-Endocrine-Therapy (SET2,3) Index had Prognostic Value that was Independent and Complementary to the 21-gene Recurrence Score (Oncotype DX Breast Recurrence Score®) in Node-Positive Breast Cancer
October 27, 2022 — Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™
September 22, 2022 -- Delphi DiagnosticsTM Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037
July 25, 2022 — Delphi Diagnostics SET2,3 Test Clarifies Therapy Options for Certain Breast Cancer Patients
June 13, 2022 — Delphi Diagnostics: SET2,3TM Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022
February 15 -- Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial
December 15, 2021 -- SET2,3™ index adds independent, complementary information to personalize breast cancer treatment